S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
The perfect AI stock under $10 (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
The perfect AI stock under $10 (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
The perfect AI stock under $10 (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
The perfect AI stock under $10 (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:MOLN

Molecular Partners (MOLN) Stock Price, News & Analysis

$4.01
-0.39 (-8.86%)
(As of 02/23/2024 ET)
Today's Range
$4.01
$4.54
50-Day Range
$4.01
$5.00
52-Week Range
$3.53
$7.32
Volume
11,468 shs
Average Volume
1,643 shs
Market Capitalization
$145.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Molecular Partners MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
12.2% Upside
$4.50 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.10) to ($2.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.40 out of 5 stars

Medical Sector

889th out of 942 stocks

Biological Products, Except Diagnostic Industry

145th out of 153 stocks


MOLN stock logo

About Molecular Partners Stock (NASDAQ:MOLN)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; as well as other third-party collaborators. It also has a collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

MOLN Stock Price History

MOLN Stock News Headlines

Molecular Partners (NASDAQ:MOLN) Trading 5.5% Higher
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Molecular Partners AG (6ML0.MU)
Molecular Partners AG ADR MOLN
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
SVB Securities Keeps Their Hold Rating on Molecular Partners (MOLN)
See More Headlines
Receive MOLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/25/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MOLN
Fax
N/A
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$4.50
Low Stock Price Target
$4.50
Potential Upside/Downside
+12.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$123.50 million
Net Margins
-686.95%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$198.70 million
Cash Flow
$3.18 per share
Book Value
$6.84 per share

Miscellaneous

Free Float
34,198,000
Market Cap
$145.76 million
Optionable
Not Optionable
Beta
0.83
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Patrick Amstutz Ph.D. (Age 49)
    Co-Founder, CEO, Member of Management Board & Director
    Comp: $722.83k
  • Dr. Michael Tobias Stumpp Ph.D. (Age 52)
    Co-Founder, Executive VP of Projects & Member of Management Board
  • Mr. Robert Hendriks
    Vice President of Finance
  • Mr. Alexander Zurcher (Age 49)
    COO & Member of Management Board
  • Ms. Renate Gloggner (Age 54)
    Executive VP of People & Community and Member of Management Board
  • Mr. Daniel Steiner Ph.D.
    Senior Vice President of Research
  • Mr. Seth D. Lewis
    Senior Vice President of Investor Relations, Communications & Strategy
  • Mr. Michael Pitzner
    General Counsel, Compliance Officer, Senior VP Legal & Business Development
  • Dr. Pamela A. Trail Ph.D. (Age 68)
    Strategic Consultant
  • Ms. Anne Goubier D.V.M.
    Ph.D., Senior Vice President of Biology














MOLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Molecular Partners stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares.
View MOLN analyst ratings
or view top-rated stocks.

What is Molecular Partners' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price targets for Molecular Partners' shares. Their MOLN share price targets range from $4.50 to $4.50. On average, they predict the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for MOLN
or view top-rated stocks among Wall Street analysts.

How have MOLN shares performed in 2024?

Molecular Partners' stock was trading at $4.18 at the start of the year. Since then, MOLN shares have decreased by 4.1% and is now trading at $4.01.
View the best growth stocks for 2024 here
.

Are investors shorting Molecular Partners?

Molecular Partners saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 58,500 shares, a decrease of 13.7% from the January 15th total of 67,800 shares. Based on an average trading volume of 13,400 shares, the days-to-cover ratio is currently 4.4 days.
View Molecular Partners' Short Interest
.

When is Molecular Partners' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our MOLN earnings forecast
.

When did Molecular Partners IPO?

(MOLN) raised $81 million in an initial public offering on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOLN) was last updated on 2/25/2024 by MarketBeat.com Staff